Hemab Therapeutics Holdings, Inc. (COAG) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analysts are broadly bullish on Hemab Therapeutics: Nine analysts give the stock a “Moderate Buy” consensus, with seven buy ratings, one hold and one sell. The average 12-month price target is $54.71, while recent targets range as high as $70.
• Institutional investors have established sizable positions: Citadel Advisors purchased approximately $19.2 million in shares, while Braidwell, State Street and other firms also initiated stakes during the second quarter.
• The company remains a high-risk clinical-stage biotech: Hemab focuses on treatments for serious bleeding disorders, including its lead candidate HMB-001, but reported a quarterly loss of $0.80 per share—worse than the expected $0.63 loss—and trades well below its 52-week high.

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $54.71.

Several brokerages recently weighed in on COAG. HC Wainwright increased their target price on Hemab Therapeutics from $52.00 to $60.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Wedbush lifted their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. assumed coverage on Hemab Therapeutics in a report on Thursday, October 15th. They set an "overweight" rating and a $70.00 price target for the company. Jefferies Financial Group increased their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Finally, Weiss Ratings cut Hemab Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday, September 25th.

Hedge Funds Weigh In On Hemab Therapeutics

Several large investors have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new stake in Hemab Therapeutics in the 2nd quarter valued at $19,226,000. Braidwell LP acquired a new position in shares of Hemab Therapeutics during the second quarter valued at about $5,877,000. State Street Corp acquired a new position in shares of Hemab Therapeutics during the second quarter valued at about $2,825,000. Opaleye Management Inc. acquired a new position in shares of Hemab Therapeutics during the second quarter valued at about $1,750,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Hemab Therapeutics in the second quarter valued at about $688,000.

Hemab Therapeutics Price Performance

COAG stock opened at $34.40 on Monday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $55.42. The company's 50-day moving average price is $39.01. The company has a market capitalization of $1.61 billion and a PE ratio of -1.39.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.17). On average, equities analysts forecast that Hemab Therapeutics will post -3.10 earnings per share for the current fiscal year.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company's research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.

Hemab's lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.